What Researchers Did
Researchers reported on a patient with severe, refractory perineal and cutaneous Crohn's disease treated with hyperbaric oxygen.
What They Found
The patient experienced dramatic relief of symptoms and regression of wounds within 2.5 months, after 8 years of unsuccessful prior therapies. While clinical remission required four subsequent courses of hyperbaric oxygen over 11 months, the patient remained largely asymptomatic with minimal cutaneous disease compared to before treatment.
What This Means for Canadian Patients
For Canadian patients with severe, treatment-resistant perineal and cutaneous Crohn's disease, hyperbaric oxygen therapy might be considered as an alternative treatment option. However, given its cost and the need for repeated treatments, it should be carefully evaluated and not used routinely.
Canadian Relevance
This study has no direct Canadian connection as it is a case report from a non-Canadian institution.
Study Limitations
As a single case report, the findings cannot be generalized to a broader patient population, and the treatment is noted to be costly and not for routine use.